Legal fallacies of antipsychotic drugs

Journal of the American Academy of Psychiatry and the Law

Volumn 35, Issue 2, 2007, Pages 235-246

  Erickson, Steven K ^a   Ciccone, J Richard ^b   Schwarzkopf, Steven B ^b   Lamberti, J Steven ^b   Vitacco, Michael J ^c  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c Mendota Mental Health Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE;

ATTENTION; COGNITION; EXTRAPYRAMIDAL SYMPTOM; FORENSIC PSYCHIATRY; FUNCTIONAL STATUS; HUMAN; INTELLIGENCE; LEGAL ASPECT; LEGAL LIABILITY; LOW DRUG DOSE; MEMORY; NEUROTOXICITY; PRISON; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; VISION;

ANTIPSYCHOTIC AGENTS; COGNITION; COMMITMENT OF MENTALLY ILL; HUMANS; INFORMED CONSENT; PREJUDICE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 34547103234     PISSN: 10936793     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (164)

1. Sharma T: Brain Imaging in Schizophrenia: Insights and Applications. London: Remedica Publishing, 2001
2. Hall D, Gogos JA, Karayiorgou M: The contribution of three strong candidate schizophrenia susceptibility genes in demographically distinct populations. Genes Brain Behav 3:240-8, 2004
3. Norton N, Williams HJ, Owen MJ: An update on the genetics of schizophrenia. Curr Opin Psychiatry 19:158-64, 2006
4. Weinberger DR: Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44: 660-9, 1987
5. Konradi C, Heckers S: Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 97:153-79, 2003
6. Miyamoto S, LaMantia AS, Duncan GE, et al: Recent advances in the neurobiology of schizophrenia. Mol Interv 3:27-39, 2003
7. Harvey PD, Koren D, Reichenberg A, et al: Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr Bull 32: 250-8, 2006
8. Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al: The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32: 214-19, 2006
9. Breier A, Schreiber JL, Dyer J, et al: National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry 48:239-46, 1991
10. Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321-30, 1996
11. Milev P, Ho B-C, Arndt S, et al: Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 162:495-506, 2005
12. Stip E, Chouinard S, Boulay LJ: On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29:219-32, 2005
13. Weiss EM, Bilder RM, Fleischhacker WW: The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology 162: 11-7, 2002
14. Perkins DO, Gu H, Boteva K, et al: Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 162:1785-804, 2005
15. Malla A, Norman R, Manchanda R, et al: Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis. Psychol Med 32:1109-19, 2002
16. Robinson D, Woerner MG, Alvir JMJ, et al: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241-7, 1999
17. Gitlin M, Nuechterlein K, Subotnik KL, et al: Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Focus 2:122-30, 2004
18. Wyatt RJ, Green MF, Tuma AH: Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data. Psychol Med 27:261-8, 1997
19. Herings RM, Erkens JA: Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Safety 12:423-4, 2003
20. Fenton WS, Blyler CR, Heinssen RK: Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 23:637-51, 1997
21. Ascher-Svanum H, Faries DE, Zhu B, et al: Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 67:453-60, 2006
22. Swartz MS, Swanson JW, Hiday VA, et al: Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. Am J Psychiatry 155:226-31, 1998
23. Nose M, Barbui C, Tansella M: How often do patients with psychosis fail to adhere to treatment programmes? - a systematic review. Psychol Med 33:1149-60, 2003
24. Ananth H, Popescu I, Critchley HD, et al: Cortical and subcortical gray matter abnormalities in schizophrenia determined through structural magnetic resonance imaging with optimized volumetric voxel-based morphometry. Am J Psychiatry 159: 1497-505, 2002
25. Bagary MS, Symms MR, Barker GJ, et al: Gray and white matter brain abnormalities in first-episode schizophrenia inferred from magnetization transfer imaging. Arch Gen Psychiatry 60:779-88, 2003
26. Burns J, Job D, Bastin M, et al: Structural disconnectivity in schizophrenia: a diffusion tensor magnetic resonance imaging study. Br J Psychiatry 182:439-43, 2003
27. Cahn W, Pol H, Bongers M, et al: Brain morphology in antipsychotic-naive schizophrenia: a study of multiple brain structures. Br J Psychiatry 181:66-72, 2002
28. Narr KL, Bilder RM, Toga AW, et al: Mapping cortical thickness and gray matter concentration in first episode schizophrenia. Cereb Cortex 15:708-19, 2005
29. Neckelmann G, Specht K, Lund A, et al: MR morphometry analysis of grey matter volume reduction in schizophrenia: association with hallucinations. Int J Neurosci 116:9-23, 2006
30. McDonald C, Bullmore E, Sham P, et al: Regional volume deviations of brain structure in schizophrenia and psychotic bipolar disorder: computational morphometry study. Br J Psychiatry 186:369-77, 2005
31. Pantelis C, Yucel M, Wood SJ, et al: Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr Bull 31:672-96, 2005
32. Styner M, Lieberman JA, McClure RK, et al: Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. Proc Natl Acad Sci USA 102:4872-7, 2005
33. Wright IC, Rabe-Hesketh S, Woodruff PWR, et al: Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 157:16-25, 2000
34. Glantz LA, Gilmore JH, Lieberman JA, et al: Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res 81:47-63, 2006
35. Jarskog LF, Glantz LA, Gilmore JH, et al: Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29:846-58, 2005
36. Roberts RC, Roche JK, Conley RR: Synaptic differences in the patch matrix compartments of subjects with schizophrenia: a postmortem ultrastructural study of the striatum. Neurobiol Dis 20:324-35, 2005
37. Cotter D, Mackay D, Chana G, et al: Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 12:386-94, 2002
38. Pantelis C, Yucel M, Wood SJ, et al: Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr Bull 31:672-96, 2005
39. DeLisi LE, Sakuma M, Tew W, et al: Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res 74:129-40, 1997
40. Mathalon DH, Sullivan EV, Lim KO, et al: Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 58:148-57, 2001
41. Woods BT: Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am J Psychiatry 155:1661-70, 1998
42. Sell v. United States, 539 U.S. 166 (2003)
43. Washington v. Harper, 494 U.S. 210 (1990)
44. Singleton v. Norris, 108 F.3d 872 (8th Cir. 1997)
45. Robbins E, Waters J, Herbert P: Competency to stand trial evaluations: a study of actual practice in two states. J Am Acad Psychiatry Law 25:469-83, 1997
46. Morse SJ: Inevitable mens rea. Harv J Law & Pub Pol'y 27:51-64, 2003
47. Viljoen JL, Zapf PA, Roesch R: Diagnosis, current symptomatology, and the ability to stand trial. J Forensic Psychol Pract 3:23-37, 2003
48. Freedman R: Schizophrenia. N Engl J Med 349:1738-49, 2003
49. Sawa A, Snyder SH: Schizophrenia: diverse approaches to a complex disease. Science 296:692-5, 2002
50. Amador XF, Flaum M, Andreasen NC, et al: Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry 51:826-36, 1994
51. Morse SJ: Involuntary competence. Behav Sci Law 21:311-28, 2003
52. Riggins v. Nevada, 504 U.S. 127 (1992)
53. Tomashefsy S: Antipsychotic drugs and fitness to stand trial: the right of unfit accused to refuse treatment. U Chi Law Rev 52: 773-94, 1985
54. Fentiman LC: Whose right is it anyway? - rethinking competency to stand trial in light of the synthetically sane insanity defendant. U Miami Law Rev 40:1109-69, 1986
55. Breneman DA: Forcible antipsychotic medication and the unfortunate side effects of Sell v. United States. Harv J Law & Pub Pol'y 27:965-85, 2004
56. Vitek v. Jones, 436 U.S. 407 (1978)
57. In te Guardianship of Roe, 421 N.E.2d 40 (Mass. 1981)
58. Riese v. St. Mary's Hosp. & Med. Ctr., 271 Cal. Rptr. 199 (Cal. Ct. App. 1989)
59. Rivers v. Katz, 495 N.E.2d 337 (N.Y. 1986)
60. Lamberti JS, Olson D, Crilly JF, et al: Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 163:1273-6, 2006
61. American Psychiattic Association: Practice Guidelines for the Treatment of Patients With Schizophrenia. Washington, DC: American Psychiatric Publishing, 2004
62. Marder SR: Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand 111: 43-6, 2005
63. Kapur S, Mizrahi R, Li M: From dopamine to salience to psychosis: linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 79:59-68, 2005
64. Berridge KC, Robinson TE: What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Rev 28:309-69, 1998
65. Sevy S, Davidson M: The cost of cognitive impairment in schizophrenia. Schizophr Res 17:1-3, 1995
66. Fenton WS, Stover EL, Insel TR: Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective. Psychopharmacology 169:365-6, 2003
67. Asarnow RF, Granholm E, Sherman T: Span of Apprehension in Schizophrenia. Amsterdam: Elsevier, 1991
68. McClure RK: The visual backward masking deficit in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 25:301-11, 2001
69. Green MF: Schizophrenia From a Neurocognitive Perspective: Probing the Impenetrable Darkness. Needham Heights, MA: Allyn & Bacon, 1998
70. Bowie CR, Harvey PD, Bowie CR: Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr Clin N Am 28:613-33, 2003
71. Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L: The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res 29:65-85, 1989
72. Nuechterlein KH, Barch DM, Gold JM, et al: Identification of separable cognitive factors in schizophrenia. Schizophr Res 72: 29-39, 2004
73. Keshavan MS, Berger G, Zipursky RB, et al: Neurobiology of early psychosis. Br J Psychiatry 187:8-18, 2005
74. Green MF, Nuechterlein KH, Gold JM, et al: Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 56:301-7, 2004
75. Lencz T, Smith CW, McLaughlin D, et al: Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry 59:863-71, 2006
76. Daban C, Martinez-Aran A, Torrent C, et al: Specificity of cognitive deficits in bipolar disorder versus schizophrenia: a systematic review. Psychother Psychosom 75:72-84, 2006
77. Toulopoulouand T, Murray RM: Verbal memory deficit in patients with schizophrenia: an important future target for treatment. Expert Rev Neurother 4:43-52, 2004
78. Calev A: Recall and recognition in chronic nondemented schizophrenics: use of matched tasks. J Abnorm Psychol 93:172-7, 1984
79. Honey GD, Fletchet PC: Investigating principles of human brain function underlying working memory: what insights from schizophrenia? Neuroscience 139:59-71, 2006
80. Park S, Holzman PS: Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry 49:975-82, 1992
81. Green MF, Marshall BD Jr, Wirshing WC, et al: Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154:799-804, 1997
82. Harvey PD, Bowie CR, Loebel A: Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine. J Neuropsychiatry Clin Neurosci 18:54-63, 2006
83. McGurk SR, Carter C, Goldman R, et al: The effects of clozapine and risperidone on spatial working memory in schizophrenia. Am J Psychiatry 162:1013-16, 2005
84. Chen C, Tonegawa S: Molecular genetic analysis of synaptic plasticity, activity-dependent neural development, learning, and memory in the mammalian brain. Ann Rev Neurosci 20:157-84, 1997
85. Brewer WJ, Francey SM, Wood SJ, et al: Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psychiatry 162:71-8, 2005
86. McKay AP, McKenna PJ, Bentham P, et al: Semantic memory is impaired in schizophrenia. Biol Psychiatry 39:929-37, 1996
87. Saykin AJ, Shtasel DL, Gur RE, et al: Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 51:124-31, 1994
88. Brerion G, Amador X, Smith MJ, et al: Mechanisms underlying memory impairment in schizophrenia. Psychol Med 27:383-93, 2000
89. Stuss DT, Alexander MP: Executive functions and the frontal lobes: a conceptual view. Psychol Res 63:289-98, 2000
90. Sharma T, Antonova L: Cognitive function in schizophrenia: deficits, functional consequences, and future treatment. Psychiatr Clin North Am 26:25-40, 2003
91. Goldman-Rakic PS: Prefrontal Cortical Dysfunction in Schizophrenia: The Relevance of Working Memory. New York: Raven Press, 1991
92. Berman I, Viegner B, Merson A, et al: Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophtenia. Schizophr Res 25:1-10, 1997
93. Mohamed S, Fleming S, Penn DL, et al: Insight in schizophrenia: its relationship to measures of executive functions. J Nerv Ment Dis 187:525-31, 1999
94. Lysaker P, Bell M: Insight and cognitive impairment in schizophrenia. Performance on repeated administrations of the Wisconsin Card Sorting Test. J Nerv Ment Dis 182:656-60, 1994
95. Brekke JS, Raine A, Ansel M, et al: Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia. Schizophr Bull 23:19-28, 1997
96. Aylward E, Walker E, Bettes B: Intelligence in schizophrenia: meta-analysis of the research. Schizophr Bull 10:430-59, 1984
97. Goldberg TE, Hyde TM, Kleinman JE, et al: Course of schizophrenia: neuropsychological evidence for a static encephalopathy. Schizophr Bull 19:797-804, 1993
98. Kremen WS, Seidman LJ, Faraone SV, et al: Intelligence quotient and neuropsychological profiles in patients with schizophrenia and in normal volunteers. Biol Psychiatry 50:453-62, 2001
99. David AS, Malmberg A, Brandt L, et al: IQ and risk for schizophrenia: a population-based cohort study. Psychol Med 27: 1311-23, 2000
100. Hassiotis A, Ukoumunne OC, Byford S, et al: Intellectual functioning and outcome of patients with severe psychotic illness randomised to intensive case management. Report from the UK700 trial. Br J Psychiatry 178:166-71, 2001
101. Chaplin R, Barley M, Cooper SJ, et al: The impact of intellectual functioning on symptoms and service use in schizophrenia. J Intellectual Disabil Res 50:288, 2006
102. Hassiotis A: Prevalence and characteristics of patients with severe mental illness and borderline intellectual functioning: report from the UK700 randomised controlled trial of case management. Br J Psychiatry 175:135-40, 1999
103. Kraepelin E: Dementia Praecox and Paraphrenia. New York: Robert E. Krieger, 1971
104. Marenco S, Weinberger DR: The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev Psychopathol 12:501-27, 2000
105. Byrd JC, Bykov V, Rothman R: Chronic haloperidol treatment up-regulates rat brain PCP receptors. Eur J Pharmacol 140: 121-2, 1987
106. Stephan KE, Baldeweg T, Friston KJ: Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry 59:929-39, 2006
107. Heresco-Levy U: Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 23:1113-23, 2003
108. Jarskog FL, Miyamoto S, Lieberman JA: Schizophrenia: new pathological insights and therapies. Ann Rev Med 58:59-71, 2006
109. Catts VS, Catts SV: Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene? Schizophr Res 41:405-15, 2000
110. Jarskog LF, Gilmore JH, Selinger ES, et al: Cortical Bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol Psychiatry 48:641-50, 2000
111. Jarskog LF, Selinger ES, Lieberman JA, et al: Apoptotic proteins in the temporal cortex in schizophrenia: high bax/bcl-2 ratio without caspase-3 activation. Am J Psychiatry 161:109-15, 2004
112. Pakkenberg B: Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry 47:1023-8, 1990
113. Young KA, Manaye KF, Liang CL, et al: Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biol Psychiatry 47:944-53, 2000
114. Jentsch JD, Roth RH: The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201-25, 1999
115. Rajkowska G, Selemon LD, Goldman-Rakic PS: Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry 55:215-24, 1998
116. Javitt DC: Is the glycine site half saturated or half unsaturated? - effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry 19:151-7, 2006
117. Lane H-Y, Chang Y-C, Liu Y-C, et al: Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 62:1196-204, 2005
118. Larsen TK, Friis S, Haahr U, et al: Early detection and intervention in first-episode schizophrenia: a critical review. Acta Psychiatr Scand 103:323-34, 2001
119. McGlashan TH: Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry 46:899-907, 1999
120. McGlashan TH, Zipursky RB, Perkins D, et al: The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res 61:7-18, 2003
121. Lieberman JA: Is schizophrenia a neurodegenerative disorder? - a clinical and neurobiological perspective. Biol Psychiatry 46:729-39, 1999
122. Weinberger DR, McClure RK: Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Arch Gen Psychiatry 49:553-8, 2002
123. McGlashan TH: Is active psychosis neurotoxic? Schizophr Bull 32:609-13, 2006
124. Clarke M, Whitty P, Browne S, et al: Untreated illness and outcome of psychosis. Br J Psychiatry 189:235-40, 2006
125. Ucok A, Polat A, Gene A, et al: Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. J Psychiatr Res 38:163-8, 2004
126. Marshall M, Lewis S, Lockwood A, et al: Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 62: 975-83, 2005
127. Keshavan MS, Haas G, Miewald J, et al: Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses. Schizophr Bull 29:757-69, 2003
128. Harrigan SM, McGorry PD, Krstev H: Does treatment delay in first-episode psychosis really matter? Psychol Med 33:97-110, 2002
129. Larsen TK, Moe LC, Vibe-Hansen L, et al: Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophr Res 45:1-9, 2000
130. Harris MG, Henry LP, Harrigan SM, et al: The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res 79:85-93, 2005
131. de Haan L, Linszen DH, Lenior ME, et al: Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication. Schizophr Bull 29:341-8, 2003
132. Loebel AD, Lieberman JA, Alvir JM, et al: Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 149:1183-8, 2003
133. Scully PJ, Coakley G, Kinsella A, et al: Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia. Psychol Med 27:1303-10, 2000
134. Amminger GP, Edwards J, Brewer WJ, et al: Duration of untreated psychosis and cognitive deterioration in first-episode schizophrenia. Schizophr Res 54:223-30, 2002
135. Rund BR, Melle I, Friis S, et al: Neurocognitive dysfunction in first-episode psychosis: correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. Am J Psychiatry 161:466-72, 2004
136. Craig TJ, Bromet EJ, Fennig S, et al: Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? Am J Psychiatry 157:60-6, 2000
137. Bottlender R, Sato T, Jäger M, et al: The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. Schizophr Res 62:37-44, 2003
138. Mossman D: Unbuckling the 'chemical straitjacket': The legal significance of recent advances in the pharmacological treatment of psychosis. San Diego Law Rev 39:1033-164, 2002
139. Winick B: The Right to Refuse Mental Health Treatment. Washington, DC: American Psychological Association, 1997
140. Erickson SK, Vitacco MJ, Van Rybroek G: Beyond overt violence: Wisconsin's progressive civil commitment statute as a marker of a new era in mental health law. Marq Law Rev 89: 359-405, 2005
141. Weickert TW, Goldberg TE: First- and second-generation antipsychotic medication and cognitive processing in schizophrenia. Curr Psychiatry Rep 7:304-10, 2005
142. Mishara AL, Goldberg TE: A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55:1013-22, 2004
143. Lieberman JA, Stroup TS, McEvoy JP, et al: The clinical antipsychotic trials of intervention effectiveness I: effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-23, 2005
144. Green MF, Marder SR, Glynn SM, et al: The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 51:972-8, 2002
145. Harvey PD, Meltzer H, Simpson GM, et al: Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 66:101-13, 2004
146. Keefe RS, Bollini AM, Silva SG: Do novel antipsychotics improve cognition? - a report of a meta-analysis. Psychiatric Ann 29:623-9, 1999
147. Meltzer HY, McGurk SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255, 1999
148. Harvey PD, Rabinowitz J, Eerdekens M, et al: Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 162:1888-95, 2005
149. Hori H, Noguchi H, Hashimoto R, et al: Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 86:138-46, 2006
150. Bender S, Dittmann-Balcar A, Schall U, et al: Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. Int J Neuropsychopharmacol 9:135-45, 2006
151. Joober R, Rouleau GA, Lai S, et al: Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers. Schizophr Res 53:229-38, 2002
152. Serper MR, Harvey PD, Davidson M: Attentional and clinical neuroleptic response in schizophrenia: a study with the continuous performance test. Cogn Neuropsychiatry 2:241-9, 1997
153. Liu SK, Chen WJ, Chang C-J, et al: Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. Neuropsychopharmacology 22: 311-19, 2000
154. Keefe RS, Young CA, Rock SL, et al: One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 81:1-15, 2006
155. Thornton AE, Van Snellenberg JX, Sepehry AA, et al: The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. J Psychopharmacol 20:335-46, 2006
156. Bilder RM, Goldman RS, Volavka J, et al: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159:1018-28, 2002
157. Stip E, Chouinard S, Boulay LJ: On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29:219-32, 2005
158. Jann MW: Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy 24:1759-83, 2004
159. Weiss EM, Bilder RM, Fleischhacker WW: The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology 162:11-17, 2002
160. Krystal JH, D'Souza DC, Mathalon D, et al: NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 169:215-33, 2003
161. Tuominen HJ, Tiihonen J, Wahlbeck K: Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 72:225-34, 2004
162. Erickson SK, Schwarzkopf SB, Palumbo D, et al: Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin Neuropharmacol 28:179-84, 2005
163. Dakhale G, Khanzode S, Khanzode S, et al: Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 49:205-9, 2004
164. Zhang XY, Tan YL, Cao LY, et al: Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 81:291-300, 2006